CMS’s aim to cut documentation will be a payment cut

When CMS proposed several changes to the Physician Fee Schedule and Quality Payment Program in July, it was under the guise that the agency was knocking off burdensome documentation requirements for physicians. Presumably, the less time doctors spent on paperwork, the more they could be with patients.

However, the agency’s own proposal states documentation time won’t actually be reduced by much—but the changes will likely come with a payment rate cut.

“CMS says it will save something like 500 years in documentation,” Drew Voytal, MPA, associate director of government affairs for the Medical Group Management Association, said during a recent presentation in Boston at the association’s annual convention.

However, digging a little further into the proposal, “CMS themselves say, really, we don’t think this will cut documentation,” Voytal said.

One key part of the proposal that will result in a payment cut is CMS’s idea to overhaul evaluation/management (E/M) coding and payment policies by creating one payment rate for four different levels of office and outpatient E/M visits. Doing so effectively reduces the payment rate for codes 4 and 5. Under the notion of cutting documentation, the proposal would actually reduce payments with few documentation adjustments.

“It’s important to know they think they buried the book about it,” Voytal said.

The association also called the proposals “misguided.”

The changes in the proposed rule are far-reaching, but the E/M coding changes have “gotten the most attention” from providers as a result of the possible rate cut, according to MGMA.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.